PA
METC icon

PharVision Advisers’s Ramaco Resources Class A METC Stock Holding History

PharVision Advisers’s Portfolio METC Stock Details METC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,178
Closed -$399K – 428
2025
Q4 		$399K Buy
+22,178
New +$583K 0.2% 127

Other funds holding METC

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Dayah Capital Stamford, Connecticut $261M AUM
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YEPI
Yorktown Energy Partners IX New York $57.5M AUM 108.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
YEPX
Yorktown Energy Partners X New York $69.5M AUM 143.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PharVision Advisers's METC Position: Q1 2026 in Review

PharVision Advisers sold out of Ramaco Resources Class A (METC) in Q1 2026, closing a stake of 22,178 shares — an estimated $399K sold.

PharVision Advisers first reported a position in METC in Q4 2025 and held it in 1 quarter. The position peaked at $399K in Q4 2025. 206 funds tracked by Wall St. Rank hold METC as of Q1 2026.

  • PharVision Advisers reported no remaining Ramaco Resources Class A position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 22,178 Ramaco Resources Class A shares in Q1 2026, an estimated $399K.
  • PharVision Advisers first reported a position in Ramaco Resources Class A in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's Ramaco Resources Class A position peaked at $399K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Ramaco Resources Class A as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.